CoChat

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Open access
Anagnostou, Valsamo, Ho, Cheryl, Nicholas, Garth, Juergens, Rosalyn Anne, Sacher, Adrian, Fung, Andrea S., Wheatley-Price, Paul, Laurie, Scott A., Levy, Benjamin, Brahmer, Julie R., Balan, Archana, Niknafs, Noushin, Avrutin, Egor, Zhu, Liting, Sausen, Mark, Bradbury, Penelope A., O’Donnell-Tormey, Jill, Gaudreau, Pierre Olivier, Ding, Keyue, Dancey, Janet · 2023 · Nature Medicine
Cited by 170

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular response-adaptive immuno-chemotherapy for patients with lung cancer. In the first of two independent stages, 50 patients with advanced non-small cell lung cancer received pembrolizumab as standard of care. The primary objectives of stage 1 were to ascertain ctDNA response and determine optimal timing and concordance with radiologic Response Evaluation Criteria in Solid Tumors (RECIST) response. Secondary endpoints included the evaluation of time to ctDNA response and correlation with progression-free and overall survival. Maximal mutant allele fraction clearance at the third cycle of pembrolizumab signified molecular response (mR). The trial met its primary endpoint, with a sensitivity of ctDNA response for RECIST response of 82% (90% confidence interval (CI): 52–97%) and a specificity of 75% (90% CI: 56.5–88.5%). Median time to ctDNA response was 2.1 months (90% CI: 1.5–2.6), and patients with mR attained longer progression-free survival (5.03 months versus 2.6 months) and overall survival (not reached versus 7.23 months). These findings are incorporated into the ctDNA-driven interventional molecular response-adaptive second stage of the BR.36 trial in which patients at risk of progression are randomized to treatment intensification or continuation of therapy. ClinicalTrials.gov ID: NCT04093167.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02598-9

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 170

Metadata

Authors
Anagnostou, V., Ho, C., Nicholas, G., Juergens, R. A., Sacher, A., Fung, A. S., Wheatley-Price, P., Laurie, S. A., Levy, B., Brahmer, J. R., Balan, A., Niknafs, N., Avrutin, E., Zhu, L., Sausen, M., Bradbury, P. A., O’Donnell-Tormey, J., Gaudreau, P. O., Ding, K., & Dancey, J.
Venue
Nature Medicine
Published
2023-10
Volume
29
Issue
10
Pages
2559-2569
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4387451565
Cited by
170
References
6
FWCI
27.01
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. https://app.cochat.ai/papers/10.1038/s41591-023-02598-9
The paper
Anagnostou, V., Ho, C., Nicholas, G., Juergens, R. A., Sacher, A., Fung, A. S., Wheatley-Price, P., Laurie, S. A., Levy, B., Brahmer, J. R., Balan, A., Niknafs, N., Avrutin, E., Zhu, L., Sausen, M., Bradbury, P. A., O’Donnell-Tormey, J., Gaudreau, P. O., Ding, K., & Dancey, J. (2023). ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nature Medicine. https://doi.org/10.1038/s41591-023-02598-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.